Reductions in adipose tissue are associated with improvements in insulin sensitivity, lipid profiles, and inflammatory markers, all of which are central to the pathogenesis of MASLD [73]. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.